Condition: Tuberous Sclerosis Complex · Epilepsy · Sponsor: Darcy Krueger
This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants. This study is supported by research funding from the Office of Orphan Products Division (OOPD) of the US Food and Drug Administration (FDA).
This description comes directly from the study's public registry record.
Molly S Griffith, BA · 513-636-9669 · info@tscsteps.org
Jessica Krefting, RN · 256-533-0833 · info@tscsteps.org
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| University of California at Los Angeles | Los Angeles, California, United States | Recruiting |
| Stanford University | Palo Alto, California, United States | Recruiting |
| Children's Hospital Colorado | Aurora, Colorado, United States | Recruiting |
| Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| Boston Children's Hospital | Boston, Massachusetts, United States | Recruiting |
| Washington University -- St. Louis | St Louis, Missouri, United States | Recruiting |
| University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Active Not Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
| University of Texas HSC at Houston | Houston, Texas, United States | Recruiting |
| Seattle Children's Hospital | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05104983